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Liver transplant has long been the ultimate treatment for patients with end-stage liver disease. 
For pediatric patients under 12 years old, the Pediatric End-Stage Liver Disease (PELD) scoring 
system has been developed and implemented for almost 10 years as an estimation of 90-day 
mortality pre-transplantation. PELD score has been used as an appropriate tool to discriminate 
patients when allocating organs, yet as a potential predictor of post-transplant graft failure, its 
effect has been somewhat inconsistent. In previous studies, researchers tended to use single 
measured PELD score at the time of listing or at transplant in predicting graft survival, while in 
clinical practice PELD scores are often calculated multiple times between listing and transplant 
to monitor patients’ disease status. To make the most use of the information of the repeated 
PELD measures, we propose to employ latent group-based trajectory models to explore the 
underlying distinct patterns of the PELD scores and then integrate such longitudinal profiles into 
survival analysis to examine its effects as a predictor of graft survival. 
Public health significance: This study will provide both the medical and public health 
communities with important information that will facilitate their evidence-based practice 
concerning pediatric patients in need of liver transplant. Researchers will get to see the big 
picture regarding this health issue since national data have been used to derive the results. They 
will have a better idea of patients’ disease status and prognosis and will be able to make 
treatment or intervention decisions with more confidence. 
EFFECTS OF LONGITUGINAL PROFILES OF PEDIATRIC END-STAGE LIVER 
DISEASE (PELD) SCORES ON POST-TRANSPLANT SURVIVAL 
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1.0  INTRODUCTION 
Liver transplantation has long been the life-saving and the ultimate treatment method in patients 
with end-stage liver diseases. [1] Unfortunately the available organ source has always been 
greatly outnumbered by patients in need of transplant and among which pediatric liver recipients 
are greatly outnumbered by adult recipients (roughly 1 to 17). [2] To address the imbalance of 
resources and needs in liver transplant, numerous organ allocation systems have been 
implemented over the years, such as the Child-Turcotte-Pugh (CTP) score. [3] Starting in 
February 27, 2002, the Pediatric End-Stage Liver Disease (PELD) scoring system has been 
developed and promoted by the United Network for Organ Sharing (UNOS) in an attempt to 
create a more objective and effective organ allocation paradigm. Unlike the CTP score, which 
divides patients into different status categories and assigns different priorities on the waiting list, 
the PELD score is a continuous scale of liver disease severity and provides the assessment of 3-
month pre-transplant mortality in pediatric patients under 12 years old. The PELD score is 
calculated using patient’s age, serum total albumin, serum total bilirubin, international 
normalized ratio (INR) for prothrombin time along with presence/absence of growth failure: [4] 
 
PELD score = 0.436 (Age <1 years old) + 0.687 log(albumin g/dL) + 0.480 log(total 
bilirubin mg/dL) + 1.87 log(INR) + 0.667 (growth failure). 
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The main goal of the PELD system is to optimize transplant benefit, which means 
maximal benefit (usually measured by additional life time gained from transplant) and minimal 
harm (measured by mortality on the waiting list). As a preoperative measure, PELD score is an 
indicator of pre-transplant mortality by its definition yet its potential as a predictor of post-
transplant outcomes such as graft survival, length of hospital stay (LOS), length of intensive care 
unit stay (LOS ICU), and post-transplant complications has not been fully realized. Several 
studies have been carried out to explore the relationship between the PELD score and post-
transplant survival where mixed results were seen. 
Cowles et al. (2008) reviewed 71 pediatric biliary atresia cases that received liver 
transplant between January 1998 and December 2006 and showed a 14% graft failure rate in 53 
kids with PELD score greater or equal to 10 versus a graft failure rate of 0% in 18 kids with 
PELD score less than 10. PELD score can be used as an informative predictor of graft failure and 
a PELD score of 10 can act as a potential cutoff. [5] 
Farmer et al. (2009) studied 122 children with 159 liver transplants from 1984 to 2008. 
Their analysis showed that without considering other covariates, PELD score over 25 was 
associated with the worst 5-year and 10-year graft survival. After adjusting for other covariates, 
the higher PELD score was still significantly associated with worse graft survival along with 
other measures like creatinine clearance. [6] Their conclusions were supported by Oh et al. 
(2010) in a retrospective, single-centered study with 113 children where a PELD score over 25 
was significantly associated with graft loss. [7] 
On the other hand, null results have also been detected by other researchers. Caroll et al. 
(2003), after analyzing 67 pediatric liver transplant cases in Chicago dated from August 1997 to 
February 2002, concluded that PELD score was only associated with post-transplant LOS but not 
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associated with 1-year post-transplant mortality or ICU LOS. [8] A similar conclusion was 
reached by Freeman et al. (2005) where they did not detect significant 1-year graft survival 
results across different PELD strata. [9] 
It should also be noted that in past studies, investigators tended to use single measured 
PELD score (at time of listing or at the time of transplant) as the predictor of the outcomes of 
interest. While in the study carried out by Bourdeux et al. (2005), they took both the PELD score 
at pre-transplant assessment and the PELD score at transplant and calculated a change score from 
the two. Their results showed that neither PELD measure taken individually was significantly 
associated with post-transplant survival whereas a higher change score in PELD is associated 
with lower post-transplant survival. [10] 
In this study, we propose to investigate whether there is any association between the 
trajectory of the PELD scores and post-transplant survival. For one patient, the trajectory of 
PELD scores actually reflects the change in his or her disease status overtime and the latent 
trends, or the patterns in PELD scores overtime may contain additional information in predicting 
patients’ post-transplant survival. We aim to explore the latent patterns of the PELD scores and 
their significance in predicting post-transplant survival. We also compared the prediction ability 
of the listing PELD, PELD at the time of transplant, change in PELD score from listing to 
transplant, and the trajectories of the PELD scores on the post-transplant survival. 
In Section 2, we describe the data source that is used for this study and introduce the 
latent group-based trajectory model. We will describe how we used this method to identify 
different trajectories of the PELD scores among transplant recipients. In Section 3, we show the 
results of our findings and conclude in Section 4. 
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2.0  METHODS 
2.1 DATA 
The data used were derived from the United Network for Organ Sharing (UNOS) Standard 
Transplant Analysis and Research (STAR) data file for the liver transplant waiting list.  Our 
analysis was restricted to pediatric liver transplant recipients, who were 12 years old or younger 
at the time of listing, who started on the waiting list on or after February 27, 2002 and received a 
liver transplant on or before June, 2010.  The dataset does not contain patients who eventually 
received a multi-organ transplant.  Patients who started or ended with a Model for the End-Stage 
Liver Disease (MELD) score measure(s) were excluded because the calculations and the ranges 
of PELD and MELD scores are different.  This ended to 4,445 patients. 
All the patients had PELD score at the time of listing and at the time of transplant.  The 
number of PELD score measurements in between the time of listing and the time of transplant 
varied from 1 to 80.  In the trajectory analysis of repeated PELD measurements, we only kept the 
measurements within 90 days prior to transplant.  We further excluded patients who had less than 
2 repeated PELD measurements.  The final analytic dataset contains 1,745 transplant recipients 
with 9,237 total PELD measurements (Figure 1).   
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Figure 1 Flowchart of UNOS PELD data set 
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In addition to the PELD scores, covariates under consideration in the analyses 
included the demographic information of recipients and donors (age, gender, race/ethnicity, and 
ABO blood type), recipient’s post-transplant outcomes (death, re-transplant, or re-transplant-free 
survival), and recipient’s lab measures at the time of listing (albumin level, total bilirubin level, 
international normalized ratio [INR], and serum creatinine level). 
 
2.2     STATISTICAL ANALYSIS 
2.2.1   Latent group based trajectory analysis 
Latent group-based trajectory analysis has been widely used in areas including 
developmental/abnormal psychology, sociology, and criminology to describe and monitor an 
individual’s psychological status over time and to predict an individual’s possibility of relapsing 
back into criminal behaviors. [11] It uses a mixture model approach to categorize subjects with 
similar longitudinal patterns into the same group.  The group-based modeling approach assumes 
that the population is composed of a mixture of distinct behavior groups and can be defined by 
its respective trajectory models.  [12] In medicine, a population may not be literally made up of 
several distinct groups, yet there may be some specific patterns or important cutoff or ranges that 
can contribute to decision making in clinical practice once identified.  We adopted this approach 
to categorize liver transplant recipients into several distinct PELD trajectory pattern groups. 
Let Y i= {yi1, yi2, yi3, …, yiT} represent the longitudinal sequence of measurements on an 
individual i over T time points and let P(Yi = yi) denote the probability of observing yi.  The 
group-based trajectory model assumes that the population is composed of a mixture of J 
underlying trajectory groups such that: 
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, 
where  denotes the unconditional probability of observing Yi = yi given subject i is in 
group j; and πj is the group membership probability, probability of subject i belongs to group j.  
Since group membership is neither arbitrarily assigned nor directly observed, group membership 
probabilities for group j, πj, j =1, .…, J, are parameters of interest and are estimated by a 
multinomial logit function: 
 
, 
where is normalized to zero thus each estimation of πj will fall between 0 and 1.  The form of 
 is decided based on the type of data to be analyzed, in this study, the PELD score 
measurement is assumed to follow a normal distribution and the linkage between time from 
listing to transplant and PELD score is established by means of a latent variable: 
 
. 
 
The current software, SAS Proc TRAJ will allow us to fit a model with up to a cubic term, where 
 is a disturbance assumed to be normally distributed with a mean of 0 and a fixed but 
unknown variance of .[13] 
 To select the best trajectory model, we first needed to decide the optimal number of 
distinct trajectory groups and then to determine the appropriate functional form for each 
trajectory.  Maximum likelihood was used for the estimation of model parameters and Wald tests 
were performed to test whether trajectory parameters and generalized logit parameters differ 
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significantly from zero.  The Bayesian information criterion (BIC) was used in model selection.  
For a given model, the BIC was calculated as follows: 
, 
where L is the value of the maximum likelihood corresponding to the model; n is the sample 
size; and k is the number of parameters under estimation.  
We fit the trajectory model starting with a basic one-group model, then the two-group 
model, and so forth until a universal maximum likelihood had been reached.  The final number 
of distinct trajectory groups was determined by the Bayes factor Bij, which was defined by 
Schwartz  and Kass, Wasserman with the form: 
. 
The Bayes factor measures the odds of each of the two competing models being the correct 
model. It is computed as the ratio of the probability of i being the correct model to j being the 
correct model. For example, a Bayes factor of 10 implies that model i is 10 times more likely 
than j.  The interpretation of the Bayes factor is summarized in Table 1.2. [11] 
Besides the statistical evidence provided using the methods above, we also incorporated 
clinical knowledge and kept the rule of parsimony in mind in model selection.  SAS Proc TRAJ 
was used to carry out the group-based modeling.  The package was first developed by Dr. Bobby 
Jones from the Carnegie Mellon University in 2001 and the last updated in December 2010.  
This package and references can be downloaded from the site  
http://www.andrew.cmu.edu/user/bjones/index.html.[14] 
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2.2.2   Survival analysis of graft failure rates 
Our outcome of interest, post-transplant graft failure was defined as the time from transplant to 
either death or re-transplant.  Our goal was to predict this outcome using a specific trajectory 
pattern of the PELD scores. 
We used the Kaplan-Meier method to estimate the unadjusted function of graft failure for 
all and for each PELD trajectory group.  The log-log survival plot and the Grambch-Therneau 
test were used to test the proportional hazards (PH) assumption.  If the PH assumption was not 
violated, a log-rank test was used to compare the functions of graft failure among different PELD 
trajectory groups.  If the PH assumption was violated, weighted log-rank tests (Peto-Peto, 
Tarone-Ware, and generalized Wilcoxon test) were performed to compare the functions. 
We compared the ability in predicting graft failure for the following 3 predictors:  the 
PELD score trajectory patterns, the PELD score at the time of listing, and the PELD score at the 
time of transplant.  Three Cox PH regression models for each of the predictors were fit.  We used 
the Akaike information criterion (AIC) and the c-statistic to evaluate the prediction performance. 
All above-mentioned analyses were redone for each of the six disease diagnoses: biliary atresia, 
acute liver failure, autoimmune disorder, cancer, metabolic disorder, and other liver disease.  All 
survival-related analyses were carried out using the package of STATA version 11. 
Data used in this study, taken from the UNOS STAR registry, are possibly the best 
dataset available thus far since it contains data across the United States after the PELD scoring 
system has been implemented until June 2010.  The only thing that might impair the statistical 
power is the results of predicting graft failure using PELD trajectory patterns.  It is highly 
probable that the sizes of trajectory groups will vary greatly and a sparse group will arise.  When 
subjects fall into PELD trajectory groups with a vastly uneven sample sizes and then is carried 
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over to the subsequent survival analysis of graft failure, such imbalance and sparseness will 
possibly lead to inflated standard error of an estimate thus resulting in inaccurate coefficient 
estimates. This is an additional criterion we considered in choosing the “best” number of PELD 
trajectory patterns in the first part of this study. 
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3.0    RESULTS 
3.1    Longitudinal Profiles of the PELD Scores 
PELD scores in the data set ranged from -11 to 77.  The best trajectory pattern was selected with 
an effort to balance the complexity of the model and optimal likelihood.  An eight latent-group 
trajectory model was chosen based on the BIC factors (Table 1, 2) [15].  However, this eight-
group model contains a sparse group with only 11 subjects, which may affect the power of 
subsequent survival analyses.  It is also worth noting that in many situations; statistically 
significantly differences among patients might not be clinically significant.  To address the above 
concerns, we chose the seven-group trajectory model as the longitudinal profiles of the PELD 
scores and carried them over into the subsequent survival analysis phase. 
Except for intercept terms, all of the coefficients of the linear and quadratic terms in the 
trajectory model were positive with a considerably small absolute value.  This indicates that 
there was only a slightly increasing trend in the PELD scores over the 90-day period prior to 
transplantation.  The final seven-group trajectory pattern had orders of 0, 2, 1, 1, 1, 2, and 2 
(0=constant, 1=linear, 2=quadratic).  Group 1 had the lowest PELD scores overtime; group 2 has 
the second lowest PELD scores over time, and so forth.  Group1 had a constant trajectory pattern 
with a mean around -3.  Group 2, although had a quadratic pattern, seemed to be clustered 
around 0 with significant but minimal slope and quadratic coefficients.  Groups 3, 4, and 5 all 
had linear trajectory patterns with mean PELD scores of 12, 20, and 26, respectively.  The two 
groups with the highest PELD scores over time (groups 6 and 7) appeared to have much more 
fluctuating trajectories (Table 3 and Figure 2). 
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Table 1 Summary of group-based trajectory analysis (n=1,745) 
   # of groups BIC  
(N= 9237) 
Orders Group 
Membership 
(%) 
Group 
Membership 
(n) 
1 -37755.60 2 100 1,745 
2 -33660.14 0 41.52 724 
1 58.48 1,021 
 
3 
 
-32225.85 
3 33.63 587 
1 38.43 671 
1 27.94 487 
 
4 
 
   -31530.11 
0 30.72 536 
2 24.82 433 
1 30.93 540 
2 13.52 236 
 
   5  
 
    -31186.15 
2 23.99 418 
0 15.95 279 
2 28.72 501 
1 24.71 431 
2 6.63 116 
 
 
6 
 
 
-31012.44 
0 23.74 414 
1 16.01 279 
2 28.05 489 
1 24.11 421 
1 7.60 133 
2 0.49 9 
 
 
 
 
 13 
Table 1 Summary of group-based trajectory analysis (n=1,745), continued 
 
 
 
7 
 
 
 
-30753.25 
0 15.50 270 
2 16.65 291 
1 16.53 288 
1 21.70 379 
1 18.96 331 
2 8.98 157 
2 1.68 29 
 
 
 
8 
 
 
 
-30591.80 
0 15.58 272 
2 16.57 289 
1 16.46 287 
1 21.48 375 
1 18.32 320 
2 6.77 118 
2 4.20 73 
2 0.62 11 
 
 
 
 
9 
 
 
 
 
-30660.04 
0 15.60 273 
2 16.60 290 
0 16.10 281 
2 0.63 12 
1 21.65 378 
1 18.42 322 
2 0.14 3 
1 8.98 157 
1 1.58 28 
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Table 2 Interpretation of Bayes factors  
Bayes Factor ( ) Interpretation 
 < 1/10 Strong evidence for model j 
1/10 <  < 1/3 Moderate evidence for model j 
1/3 <  < 1 Weak evidence for model j 
1 <  < 3 Weak evidence for model i 
3 <  < 10 Moderate evidence for model i 
 > 10 Strong evidence for model i 
 
Table 3 Maximum likelihood estimates for the seven PELD trajectory groups 
Group Parameter Estimate Standard error Prob > |T| 
1 intercept -6.73 0.23 <0.0001 
 
2 
intercept 1.08 0.33 0.0012 
linear 0.05 0.02 0.0051 
quadratic 0.00051 0.0002 0.0328 
3 intercept 11.82 0.285 <0.0001 
linear 0.037 0.006 <0.0001 
4 intercept 20.15 0.266 <0.0001 
linear 0.048 0.0054 <0.0001 
5 intercept 25.76 0.26 <0.0001 
linear 0.068 0.0063 <0.0001 
 
6 
intercept 37.51 0.46 <0.0001 
linear 0.25 0.033 <0.0001 
quadratic 0.001 0.0004 0.0066 
 
7 
intercept 48.5 0.645 <0.0001 
linear 0.24 0.055 <0.0001 
quadratic 0.0015 0.00075d 0.0474 
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Figure 2 Plots for the seven groups PELD trajectories 
 
3.2    Overall Graft Survival for All Patients 
Among the 1,705 pediatric patients with non-missing graft survival information, 313 (18.36%) of 
them died or underwent re-transplantation with the majority of these events happening within 1-
year of transplantation.  The 1-year graft failure rate was 13.4% and the 5-year graft failure rate 
was about 20%.  The median follow-up time for all patients was 721 days (about 2 years) and the 
longest follow-up time was about 8 years (Figure 3). 
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Figure 3 Overall Graft Survival Functions with Confidence Interval 
3.3    Graft Survival for Patients with Different Trajectory Patterns 
At first glance, patients in group 2 and 3 had the lowest graft failure rates (15.8% and 16.2% 
respectively) and patients in group 5 and 6 had the highest graft failure rates (23.6% and 20.9%; 
hazard ratios 1.30 & 1.18, using Group 1 as reference) (Table 4). Based on the results of log-rank 
test, the survival experiences among trajectory groups did not significantly differ from each 
other. Because the sequence of trajectory groups was decided by the actual values of the PELD 
score, a test of trend was carried out to assess whether there was a significant trend for increasing 
graft failure rate with increasing PELD scores, the p-value associated with the test of trend was 
still not statistically significant (Table 5). 
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Table 4 Graft failure rates across different PELD trajectory groups (N=1,705) 
Group N % Average 
Listing 
PELD 
Average 
Transplant 
PELD 
Median 
Follow-up 
time (Days) 
Range of Follow-up 
Time (min, max) 
Censoring 
(n, %) 
1 163 15.43 -7 -5.94 721 2592 (1, 2593) 214, 81.4 
2 285 16.72 0.46 1.73 739 2920 (1, 2921) 240, 84.2 
3 84 16.66 9.73 11.75 766 2902 (1, 2903) 238, 83.8 
4 73 21.88 16.49 19.54 481.5 2923 (1, 2924) 312, 83.7 
5 22 18.89 22.92 26.31 642 2899 (1, 2900) 246, 76.4 
6 48 8.68 29.53 35.93 695 2569 (1, 2570) 117, 79.1 
7 10 1.76 45 46.33 723.5 2573(1, 2574) 25, 83.3 
 
Table 5 Log-rank tests of graft survival functions for different PELD trajectory groups, listing PELD and 
transplant PELD (n=1,705) 
Test Test of Equality Test of Trend 
Chi2 p-value Chi2(1) p-value 
PELD 
Trajectory 
Groups 
 
10.58 
 
0.1021 
 
2.84 
 
0.0918 
Listing PELD 11.37 0.0776 -- -- 
Transplant 
PELD 
10.63 0.1003 -- -- 
 
It should be noted that group 1, the group with the lowest PELD scores, did not end up 
with the highest graft survival rate, which in a way, contradicts the common notion that the lower 
the PELD score, the better the patient’s prognosis. However, patients in group 7, the group with 
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the highest PELD scores, turned out to have better graft survival than patients in group 5 and 6. 
Such abnormal outcomes may be the hint that there are some other variables that are 
complimentary to the PELD-score trajectory patterns in explaining patients’ graft survival 
experiences (Figure 4). 
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Figure 4 Graft Survival Functions for Different PELD Trajectory Groups 
 
 
3.4   Graft Survival for Patients with Different Diagnoses 
Etiology has long been regarded as an important predictor of the prognosis for patients with liver 
transplant.  In this sample, we divided patients’ primary diagnoses into 6 main groups.  About 
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50% of all patients suffered from biliary atresia.  The second most common etiology was 
metabolic disorder.  Other diagnoses included acute liver failure, autoimmune disorder, cancer, 
and miscellaneous (Table 6). 
Table 6 Graft failure rates across different diagnosis groups (N=1,705) 
Diagnosis n % Average 
listing 
PELD 
Average 
final 
PELD 
Median 
follow-up 
time (Days) 
Range of follow-up 
time (min, max) 
Censoring 
(n, %) 
110 Acute 
liver failure 
165 9.68 27.42 24.57 695 2571 (1, 2572) 133, 80.6 
206 Auto-
immune 
disorder 
64 3.75 12.55 13.78 703.5 2917 (7, 2924) 55, 85.9 
207 Cancer 164 9.62 3.29 0.92 647 2591 (1, 2592) 118, 72.0 
208 
Metabolic 
disorder 
245 14.37 3.54 6.12 742 2919 (2, 2921) 203, 82.9 
210 Other 203 11.91 11.92 13 721 2898 (1, 2899) 166, 81.8 
211 Biliary 
atresia 
864 20.67 14.16 18.3 724 2888 (1, 2889) 717, 83.0 
 
Unlike what we have seen for the PELD-score trajectory groups, cancer patients had 
higher graft failure rate compared to patients with other diagnoses (graft failure rate = 28% and 
the median follow-up time = 642 days).  For other diagnoses, the graft failure rates ranged from 
14.1% to 19.4% (mean = 17.3%) and the median follow-up time excluding cancer patients was 
722 days (Table 7).  The Kaplan-Meier survival curves for all groups excluding cancer patients 
seem to separate slightly during the first two years post-transplantation and then joined each 
other closely afterwards.  We can also see that patients with acute liver failure had the second 
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worst outcomes: there was a sudden drop in survival probability during the starting period of 
follow-up and the survival probability remained stable afterwards.  Patients with autoimmune 
disorder and biliary atresia had relatively lower graft failure rates (Figure 5). 
Table 7 Tests of equality of survival functions for different diagnosis groups (N=1,705) 
Test Test of Equality 
Chi2(5) p-value 
Breslow 8.71 0.1210 
Peto-Peto 11.26 0.0465 
Tarone-Ware 10.02 0.0746 
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Figure 5 Graft Survival Functions for Different Diagnosis Groups 
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3.5   Trajectory Groups vs. Diagnosis Groups 
As trajectory groups and the diagnosis groups are the two main predictors explored in this 
project, it was essential to explore the cross-distribution of these two.  The results may provide 
some clue to give a better explanation of our findings so far (Table 8). 
Table 8 Cross distribution of diagnosis vs. trajectory groups (N=1,705) 
Group Diagnosis Total 
Acute 
Liver 
Failure 
Autoimmune 
Disorder 
Cancer Metabolic 
Liver 
Disease 
Other Biliary 
Atresia 
1 1 8 94 89 33 38 70 
2 4 14 57 70 54 86 91 
3 10 10 6 33 40 185 288 
4 34 13 2 15 20 289 379 
5 76 11 4 20 27 184 331 
6 34 7 0 13 18 76 157 
7 6 1 1 5 11 6 29 
Total 165 64 164 245 203 864 1,705 
**Pearson chi2(30) = 805.2603   Pr < 0.001 
More than 57% of cancer patients turned out to fall into trajectory group 1, which had the 
lowest PELD scores but not the lowest graft failure rate as we found.  Another diagnosis group 
that was disproportionally distributed among the PELD-score trajectory groups was acute liver 
failure.  It was not hard to find out that cancer and acute liver failure were the two diagnoses 
whose survival curves stood out among all the diagnosis groups.  To better analyze the effect of 
 22 
PELD-score trajectory groups on graft survival with least noise as possible, we analyzed the data 
again with cancer patients excluded from the data set.  The characteristics of cancer patients were 
reported and discussed separately. 
3.6   Graft Survival Excluding Cancer Patients 
After removing the cancer patients from the data set, groups 5 and 6 had significantly higher 
graft failure rates while group 1 and 2 had the lowest graft failure rates.  The trajectory pattern 
became a significant predictor of graft survival experience (p=0.0263).  Besides, all the tests of 
equality of survival functions as well as the tests for trend were highly significant.  The influence 
of the PELD-score trajectory tends to be more obvious with the absence of cancer patients (Table 
9, 10, and Figure 6). 
Table 9 Graft failure rates across PELD trajectory groups excluding liver cancer patients (N=1,541) 
Group n % Average Listing 
PELD 
Average 
Transplant 
PELD 
Median 
Follow-up 
time (Days) 
Range of Follow-up 
Time (min, max) 
Censoring 
(n, %) 
1 169 10.97 6.73 5.70 745 2592 (1, 2593) 146, 86.4 
2 228 14.80 0.80 1.35 730.5 2920 (1, 2921) 198, 86.8 
3 278 18.04 9.79 11.74 744.5 2902 (1, 2903) 234, 84.2 
4 371 24.08 16.47 19.53 780 2923 (1, 2924) 311, 83.8 
5 318 20.64 22.88 26.31 510.5 2899 (1, 2900) 244, 76.7 
6 148 9.60 29.53 35.93 668 2569 (1, 2570) 117, 79.1 
7 29 1.88 45.13 46.51 683 2573(1, 2574) 24, 82.7 
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Table 10 Log-rank tests of graft survival functions for different PELD trajectory groups, listing PELD and 
transplant PELD excluding liver cancer patients (n= 1,541) 
Test Test of Equality Test of Trend 
Chi2 p-value Chi2(1) p-value 
PELD 
Trajectory 
Groups 
 
14.92 
 
0.0209 
 
9.80 
 
0.0017 
Listing PELD 15.27 0.0183 --- --- 
Transplant 
PELD 
14.91 0.0209 --- --- 
 
0.
70
0.
75
0.
80
0.
85
0.
90
0.
95
1.
00
Es
tim
at
ed
 S
ur
vi
va
l P
ro
ba
bi
lit
y
29 21 11 9 9 5 3 1 0Group7
148 90 63 48 33 22 8 1 0Group6
318 188 143 109 84 57 31 7 0Group5
371 248 197 146 110 65 33 11 1Group4
278 179 143 118 86 57 33 7 0Group3
228 158 114 93 69 45 25 3 0Group2
169 107 89 66 46 25 13 1 0Group1
Number at risk
0 1 2 3 4 5 6 7 8
Graft Survival Time(Years)
Group1 Group2
Group3 Group4
Group5 Group6
Group7
Kaplan-Meier Survival Functions for Different Trajectory Groups
 
Figure 6 Graft survival functions for different PELD trajectory groups excluding liver cancer patients 
After taking cancer patients out of the data set, the graft failure rates among different 
diagnosis groups were not significantly different from one another (Table 11, Table 7, and Figure 
7).  If we compare the test results in Table 6 (with liver cancer patients) and Table 9 (without 
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liver cancer patients), the difference was a good reflection of the specificity of the survival 
outcomes for the cancer patients.  The prediction power of PELD was sufficient for patients 
diagnosed with biliary atresia, metabolic disorder, acute liver failure, and autoimmune disorder, 
but may not be sufficient for cancer patients. 
Table 11 Tests of equality of graft survival functions for different diagnosis groups excluding liver cancer 
patients (n =1,541) 
Test Test of Equality 
Chi2(4) p-value 
Breslow 1.61 0.8065 
Peto-Peto 1.05 0.9024 
Tarone-Ware 1.16 0.8840 
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Figure 7 Graft survival functions for different diagnosis groups excluding liver cancer patients 
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Listing PELD score and transplant PELD, the first and last possible PELD measures for 
every patient, have been used by other researchers as the primary predictor for post-transplant 
survival. Although this project seeks to explore the longitudinal profile of PELD score as 
predictor of post-transplant graft survival, it was also of interest to find out about the effects of 
listing and transplant PELD score and compare to that of trajectory pattern.  
Our analyses showed that both listing and transplant PELD scores were statistically 
significant predictors of graft survival: the higher the listing/transplant PELD scores, the higher 
the graft failure rate.  To compare the Cox models based on listing PELD, transplant PELD, and 
trajectory PELD, Akaike information criterion (AIC) was used because none of the 3 models 
were nested within another.  The results showed that the model with transplant PELD as a single 
predictor had slightly lower AIC than the other two models (Table 12). 
Table 12 Comparison of 3 Cox models of graft survival (n =1,541) 
Predictor p-value Log likelihood AIC BIC 
Trajectory 0.0263 1878.052 3768.10 3800.15 
Listing PELD 0.0043 
*HR=1.0122 
1881.130 3764.26 3769.60 
Transplant 
PELD 
0.0291 
*HR=1.0095 
1882.827 3767.65 3773.00 
3.7   Additional Analysis I: Change in PELD Score from Listing to Transplant 
In the current data set with 1,541 patients, PELD trajectories, listing PELD, and transplant PELD 
all had been identified as significant predictors of graft survival.  To create a simpler or more 
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effective model that can accommodate two or more of these predictors, we created a change 
measure in PELD score from listing to transplant as done so by previous researchers. [11] 
The change score for PELD was calculated by subtracting the listing PELD score from its 
counterpart at the time of transplant so this measure would be positive for most patients.  The 
change scores had a mean of 2.62 and a median of 2 and were approximately normally 
distributed.  Using a paired-sample t-test, the change score was significantly larger than 0 
(p<0.0001), meaning that transplant PELD was significantly higher than the listing PELD. 
3.8   Additional Analysis II: Potential Cut-off Point of the PELD Scores 
Although the model with transplant PELD was identified as the statistically best model, the 
PELD trajectories still have their special merits given that they were derived using all the PELD 
scores within a 90-day period at the time of transplant.  Groups 5 and 6 had the highest graft 
failure rates and their corresponding PELD scores were above 25 in general.  The group with the 
next highest PELD scores (group 4) has a mean PELD score of 20.  Based on these results, we 
tried to use 25 as a potential cut-off point for the listing and transplant PELD scores. 
The results showed that about 20% of the patients had a listing PELD score greater than 
25 while for transplant PELD, this proportion increased to 28.2%, which reflects the same trend 
of increase in PELD scores overtime as trajectory pattern.  We also found that among those who 
died or underwent re-transplantation, the proportion of listing/transplant PELD scores greater 
than 25 was significantly higher than those who ended up censored.  The proportion of graft 
failure among patients with a listing PELD score >25 and <25 was 21% and 16.45%, 
respectively (p=0.054).  When using 25 as a cut-off for transplant PELD, the difference in graft 
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failure rates between the 2 groups was highly significant: 21.4% vs. 15.35% (p=0.008) (Table 
13). 
Table 13 Using 25 as the cut-off in listing and transplant PELD scores (n =1,541) 
 Listing PELD Transplant PELD 
 
    
# of Censoring 1,030 244 932 342 
# of Events 202 65 174 93 
Total 1,232 309 1,106 435 
Chi2(1) 3.7122 6.9501 
p-value 0.054 0.008 
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4. 0   DISCUSSION 
4.1   Longitudinal Profile of PELD Scores: 
Statistical Significance vs. Clinical Significance 
As a criterion in the selection of trajectory patterns, all parameter estimates and group 
membership should be significant at a 0.05 level.  The 7-group trajectory pattern we chose 
sufficed the criterion above; its coefficients for linear and quadratic terms were all very close to 
0, which mean that the magnitude of the change in PELD scores, whatever the direction, was not 
large in an absolute sense.  To take one step further, most of the lower PELD- score trajectory 
groups (groups 1-4) tended to have more flat curves than the higher PELD-score groups (groups 
5-7).  This suggests that patients with lower PELD scores, deemed to be less severe in their 
diseases, will also appear to be more stable overtime.  Groups 6 and 7 have more obvious 
fluctuations in the PELD scores.  This may be caused by smaller sample sizes, which allow for 
larger variability. 
Results from the trajectory pattern analyses were echoed by the change score in PELD 
from listing to transplant, which had a mean value of 2.62 and a median of 2, while the range of 
PELD score in this data set was as large as 88.  Although statistically significant, this difference 
may not be important in actual clinical practice.  Statistically, given a sample size over 1, 500, 
substantial power of all the analyses is guaranteed.  This is because that the variances of the 
measures will become very small such that even a slight change will end up a statistically 
significant.  However, in clinical practice, which focuses on treating individual cases, the 
magnitude of the absolute difference often exceeds statistical significance.  For a measure like 
the PELD score, which is measured under the same system, could still conceal the possible bias 
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and errors in its derivation and recording.  When we take such potential problems into account, a 
mean difference between 2 to 3 may be rendered more non-significant for clinical practitioners 
than to biostatisticians.  
On the other hand, the primary purpose of this project was to explore the underlying 
longitudinal patterns of the repeated PELD measures.  Such trajectory patterns make use of all 
the PELD measures within 90 days prior to transplant and could provide some insight into the 
change in a patient’s disease status which cannot be provided by a single measure of the PELD 
score.  
There was a relatively small group in our 7-group trajectory patterns but it did not have 
the worst graft survival as indicated by its highest PELD scores.  After examining data carefully, 
this group can be set aside as the miscellaneous group, as well as the fraction of patients with 
rarely high PELD scores.  Combined with etiology, it is possible for patient from any diagnosis 
group to demonstrate a very high PELD score, yet such high values in PELD scores are not quite 
prevalent in clinical practice.  When such cases arise in practice, it is feasible for clinicians to 
treat such patients with individualized plans.  It is reasonable to pay more serious attention to 
patients in this group from the public health or population perspectives.  
When a potential recipient enters the organ allocation system with a PELD score over 25, 
clinicians can have some confidence to say that in addition to what will happen during the 
waiting period, he or she will also have a non-optimal post-transplant survival experience.  
Clinicians will be more certain about their prediction if a transplant PELD score >25 is observed.  
This may not always be true for every patient but it will help the decision in organ allocation and 
patient prioritization. 
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4.2   “Best” Predictor of Post-transplant Survival:  
Trajectory Pattern vs. Listing/Transplant PELD 
In previous studies, PELD was used as a predictor of mortality on the waiting list as it had been 
designed to.  There are also some researchers who used single measure of PELD along with 
other covariates like donor factors to form a model to predict patients’ post-transplant survival.  
However, previous studies were usually carried out using data from one medical center with a 
sample size around 100.  We took the advantage of our resource of national data with over 1,500 
patients to rerun the analyses with single PELD measure as predictor along wiht listing and 
transplant PELD scores for comparison. 
The PELD trajectory patterns, the listing PELD, and the transplant PELD have all been 
shown to be statistically significant in predicting graft survival.  It is more convenient to use a 
single measured PELD as a predictor given it would provide as strong statistical power as that 
provided by the trajectory patterns, which may be difficult and time consuming to derive.  In our 
case, transplant PELD was the most statistically favorable by comparing AIC’s of all the models, 
but its superiority was not evident.  Still, trajectory PELD will provide additional information 
regarding patients’ status overtime with parameter estimates for the actual pattern. Additionally, 
the application of trajectory pattern will facilitate the identification of rare or miscellaneous sub-
group in the whole population as the way group 7 was identified in this project.     
To obtain a balance between the concern of having to pick single PELD measure among 
numerous records available and the complexity of trajectory pattern, a change score in PELD 
from initial listing to final transplant is worth looking into. 
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4.3   “Best” Predictor of Post-transplant Survival:  
Trajectory Pattern vs. Etiology 
The PELD scoring system was designed to act as an estimation of mortality on the waiting list 
and optimize organ allocation while regarding post-transplant survival estimation, measures like 
PELD score may not be the first choice for the majority.  It will definitely raise the significance 
of PELD score in practice if it can be proven to be informative throughout patients’ whole 
process of liver transplantation, yet the importance of etiology should never be overlooked. 
After excluding cancer patients, the graft survival among the rest of the diagnosis groups 
were not significantly different from each other (p=0.8929).  The Kaplan-Meier plot, 
complimentary to statistical tests, showed some interesting distinction among etiologies.  The 
most obvious drops in survival probabilities could be observed in the first two years after 
transplantation and stayed stable from years 3 to 8.  The survival curves crossed with each other 
during the whole study period, which indicated that relative hazards among etiologies had not 
been proportional over time (p=0.004).  This phenomenon is foreseeable since diseases differ in 
their timelines and severity and the respective treatments for different diseases will trigger 
divergent curative and side effects among patients, which will also have impacts on graft failure.  
Liver cancer patients, initially included in the data set and then taken out, clearly stand 
out by themselves regarding the outcome of interest. It is well known that the primary regimens 
for most liver cancer cases are hepatectomy and chemotherapy, liver transplant is a potential 
treatment but more appropriate for liver cancer patients with complications such as cirrhosis, or 
metastatic cancer in the liver or for whom the tumor size is relatively small.  The treatments 
specific to cancer as compared to other liver diseases will strongly influence quality of life and 
outcomes of a patient. 
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The primary reason for excluding cancer patients lies in the fact that they tend to have a 
distinct survival experience.  Liver cancer is a leading cause of death for Americans with a 5-
year survival rate of only 28% [16], while for patients in the UNOS data set; the survival rate at 
the 8th year is as high as 78%.   Second, liver transplant is regarded as the primary treatment for 
a special sub-group of all liver cancer patients as mentioned above so cancer patients in the 
current data may not be representative of its underlying population.  Third, cancer patients turn 
out to have unusually low PELD scores as the majority of them belong to group 1 in PELD 
trajectory pattern and such uneven distribution can be problematic for secondary analysis.  Also, 
the proportion of cancer patients is not high to start with (less than 10%) so its exclusion will not 
affect the statistical power of our analysis. 
It is true that etiology is important for prognosis, yet its variation and possible 
complication will make it hard to make inferences to trace the real reasons for a certain kind of 
result. For patients in need of liver transplant, etiology can be taken into consideration and must 
be handled carefully. 
4.4   Strengths, Weaknesses, and Future Plans 
This project is one of the very first to explore the longitudinal profiles of PELD measures and 
associate them with post-transplant survival.  We have also conducted these analyses using 
recently updated national registry data to ensure the generalizability and power. 
As an exploratory research project, new questions always arise as the analysis results 
accumulate.  The survival analysis was carried out univariately without adjusting for potential 
confounding variables, such as the donor factors and the presence of certain complications in 
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patients.  Also, the data we have may not suffice certain assumptions of the Cox proportional 
hazards model thus alternative methods should be recognized.   
The use of traditional survival analysis is an intuitive and convenient way and the 
trajectory pattern of repeated measurements is not necessarily the best predictor available.  In 
future studies, more advanced methodology could be applied to answer the questions proposed. 
Other researchers have proposed to combine trajectory analysis with propensity scores or to 
model trajectory pattern and survival functions jointly in one model.  In summary, liver 
transplant/graft survival is an important medical issue that needs to be studied and reported 
continuously. 
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5.0     CONCLUSION 
The PELD score has been proven to be a statistically important predictor for both pre and post 
liver transplant survival experiences, and its usage can be realized in different forms: researchers 
can choose from PELD score trajectory pattern, listing/transplant PELD score, change score in 
PELD from listing to transplant, as well as a cut-off of 25 based on their specific research 
questions and data available; medical practitioners can make use of such evidence to support 
their clinical decision. As our primary interest, PELD score trajectory has its own advantages in 
that it is a detailed description of the changes in patient’s disease status overtime and it can help 
identify underlying group(s) and particular subgroup. 
 Etiology is a key component for prognosis and should still be given attention in future 
studies. Because PELD score is designed to disregard etiology and waiting list time when 
allocating organs, all end-stage liver diseases (excluding liver cancer) do not actually differ that 
much regarding post-transplant graft survival. Liver cancer patients, due to their specific 
treatments and survival experiences, need to be studied separately. 
 More advanced techniques such as propensity score, joint modeling can be applied and 
more covariates can be incorporated to gain deeper knowledge in this field, and such research 
will carry on as the UNOS data registry keeps updating. 
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